| Combination of | |
|---|---|
| Fosfomycin | Phosphonic acid |
| Tobramycin | Aminoglycoside |
| Clinical data | |
|
Routes of administration | Inhalation |
Fosfomycin/tobramycin is a formulation of fosfomycin and tobramycin. Fosfomycin is a phosphonic acid antibiotic active against gram-positive and gram-negative. Tobramycin is an aminoglycoside with gram-negative activity. It is an inhaled medication targeting those with cystic fibrosis and is currently being studied by Gilead Sciences the United States Food and Drug Administration and the NIH General Clinical Research Center. [1]
See also
References
- ^ Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, et al. (2011). "Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients with Pseudomonas Airway Infection". Am J Respir Crit Care Med. 185 (2): 171–8. doi: 10.1164/rccm.201105-0924OC. PMC 3361752. PMID 22095545.
| Combination of | |
|---|---|
| Fosfomycin | Phosphonic acid |
| Tobramycin | Aminoglycoside |
| Clinical data | |
|
Routes of administration | Inhalation |
Fosfomycin/tobramycin is a formulation of fosfomycin and tobramycin. Fosfomycin is a phosphonic acid antibiotic active against gram-positive and gram-negative. Tobramycin is an aminoglycoside with gram-negative activity. It is an inhaled medication targeting those with cystic fibrosis and is currently being studied by Gilead Sciences the United States Food and Drug Administration and the NIH General Clinical Research Center. [1]
See also
References
- ^ Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, et al. (2011). "Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients with Pseudomonas Airway Infection". Am J Respir Crit Care Med. 185 (2): 171–8. doi: 10.1164/rccm.201105-0924OC. PMC 3361752. PMID 22095545.